Author:
Jimeénez José Luis,Resino Salvador,Martinez-Colom Alberto,Bellón José Mª,Ángeles Muñoz-Fernández Mª
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)
Reference20 articles.
1. Walmsley S. Individualized therapy for the treatment-experienced patient. AIDS Reader2003; 13: S11–15.
2. Resino S, Bellón JM, Ramos JT et al. Salvage antiretroviral therapy in HIV-infected children: advantages of lopinavir-ritonavir. Pediatr Infect Dis J2004; 23: 923–30.
3. Saez-Llorens X, Violari A, Deetz CO et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J2003; 22: 216–24.
4. Fraaij PL, Neubert J, Bergshoeff AS et al. Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children. Antivir Ther2004; 9: 297–9.
5. Mo H, King MS, King K et al. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J Virol2005; 79: 3329–38.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献